Innovative Industrial Properties (IIPR) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
5 May, 2026Business overview and portfolio
Diversified REIT with $2.5B invested capital, 110 properties across 19 states, and $69M Q1 2026 revenue.
Portfolio is 93% cannabis, 6.8% life sciences, and 0.2% other, with a weighted average lease length of 12.4 years.
Over $1B in dividends paid since 2016 inception; $270M committed to life sciences.
Properties leased to 35+ tenants, with 90% industrial and 2% retail property mix.
Investment highlights and strategy
Triple-net lease model with long-term, parent-guaranteed leases and no recurring capex.
Strong initial yields, annual escalators, and diligent underwriting focused on best-in-class operators.
$270M investment in IQHQ for life sciences, with 13.5%–15% yields and right of first offer on asset sales.
8% CAGR projected for cannabis industry (2025–2030); AI-driven growth in life sciences.
Financial performance and balance sheet
7% CAGR in AFFO/share and 9% CAGR in dividends/share from 2020 to Q1 2026.
Total return since inception exceeds 360%, outperforming RMZ and S&P 500.
Debt to total gross assets at 13%, with $176M+ liquidity and investment grade BBB+ rating.
$291.2M unsecured senior notes due May 2026 and $187.5M revolving credit facility.
Latest events from Innovative Industrial Properties
- Q1 2026 revenue was $69M, but tenant defaults and debt maturity threaten ongoing viability.IIPR
Q1 20265 May 2026 - 2025 featured robust financials, strategic diversification, and strong governance ahead of key shareholder votes.IIPR
Proxy filing23 Apr 2026 - 2025 revenues hit $266M; life sciences investment and leasing drive growth amid tenant challenges.IIPR
Q4 202524 Feb 2026 - Q2 revenue up 4% to $79.8M, AFFO $2.29/share, 95.6% leased, and dividend up 4.4%.IIPR
Q2 20242 Feb 2026 - Q3 2024 revenue was $76.5M, AFFO $64.3M, and portfolio was 95.7% leased.IIPR
Q3 202415 Jan 2026 - 2024 revenue steady at $308.5M; strong liquidity, high occupancy, and PharmaCann lease resolution.IIPR
Q4 202423 Dec 2025 - 2024 saw record revenue, strong governance, and enhanced ESG and compensation practices.IIPR
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with board support for all.IIPR
Proxy Filing1 Dec 2025 - Q1 2025 revenue and net income fell on tenant defaults, but liquidity and leasing remain strong.IIPR
Q1 202524 Nov 2025